{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:40:45Z","timestamp":1759452045654,"version":"build-2065373602"},"reference-count":7,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.vaccine.2022.05.015","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:59:05Z","timestamp":1652317145000},"page":"3818-3820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety of Pfizer-BioNTech vaccine in a cohort of healthcare providers: Differences between na\u00efve and previously infected by SARS-CoV-2"],"prefix":"10.1016","volume":"40","author":[{"given":"Andrea","family":"Chong-Valbuena","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"De-Jes\u00fas-Mar\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Agurto-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc","family":"Puchades-Gimeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Melero-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.05.015_b0005","unstructured":"Health Alert and Emergency Co-ordination Centre (CCAES). Ministry of Health, Consumer Affairs and Social Welfare. Actualizaci\u00f3n n\u00b0 321. Enfermedad por el coronavirus (COVID-19). 26.02.2021 Available at: https:\/\/www.mscbs.gob.es\/profesionales\/saludPublica\/ccayes\/alertasActual\/nCov\/documentos. \/Actualizacion_321_COVID-19.pdf."},{"key":"10.1016\/j.vaccine.2022.05.015_b0010","unstructured":"Interterritorial Council of the National Health System. Vaccination strategy against COVID-19 in Spain. COVID-19 Technical Vaccination Working Group, Vaccination Program and Registration Presentation; 2 December 2020. [consulted the 17\/1\/2021]. Available at www.mscbs.gob.es\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/covid19\/docs\/C OVID-19_EstrategiaVacunacion.pdf."},{"key":"10.1016\/j.vaccine.2022.05.015_b0015","unstructured":"EMA COVID-19 vaccine safety update 28\/01\/2021COMIRNATY BioNTech Manufacturing GmbH. Available at https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-s afety-update-comirnaty-january-2021_en.pdf."},{"key":"10.1016\/j.vaccine.2022.05.015_b0020","unstructured":"Spanish Society of Inmunology (SEI). Positioning of the Spanish Society of Inmunology (SEI) on vaccination in patients who have already overcome COVID-19. Link to report: https:\/\/www.inmunologia.org\/index.php\/covid-19. 2021."},{"issue":"27","key":"10.1016\/j.vaccine.2022.05.015_b0025","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.05.015_b0030","doi-asserted-by":"crossref","unstructured":"Krammer F, Srivastava K. PARIS team, Simon V. Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med 2021; 384: 1372-1374 Available at: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMc2101667","DOI":"10.1101\/2021.01.29.21250653"},{"key":"10.1016\/j.vaccine.2022.05.015_b0035","unstructured":"Institute of Health Carlos III, Ministry of Science and Innovation. Ministry of Health, Consumer Affairs and Social Welfare. Estudio ENE-COVID: Cuarta Ronda Estudio Nacional de sero-epidemiolog\u00eda de la Infecci\u00f3n por Sars-Cov-2 en Espa\u00f1a. Available at: https:\/\/www.mscbs.gob.es\/gabinetePrensa\/notaPrensa\/pdf\/15.12151220163348113.pdf."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:13:32Z","timestamp":1759403612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22005862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":7,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0264410X22005862"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.015","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of Pfizer-BioNTech vaccine in a cohort of healthcare providers: Differences between na\u00efve and previously infected by SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}